BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36309887)

  • 1. [Lipid accumulation in the pancreas: clinical significance of NAFPD (non-alcoholic fatty pancreas disease)].
    Jermendy G
    Orv Hetil; 2022 Oct; 163(44):1735-1742. PubMed ID: 36309887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review.
    Romana BS; Chela H; Dailey FE; Nassir F; Tahan V
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):547-554. PubMed ID: 29595117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.
    Filippatos TD; Alexakis K; Mavrikaki V; Mikhailidis DP
    Dig Dis Sci; 2022 Jan; 67(1):26-41. PubMed ID: 33469809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty pancreas disease - practices for clinicians.
    Pinte L; Balaban DV; Băicuş C; Jinga M
    Rom J Intern Med; 2019 Sep; 57(3):209-219. PubMed ID: 30901317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Pancreas Disease: The Unsung Disease.
    Sevim BC; Chela H; Ertugrul H; Malik LS; Malik S; Basar O; Daglilar E; Samiullah S; Gaballah AH; Tahan V
    Endocr Metab Immune Disord Drug Targets; 2023; 23(4):485-493. PubMed ID: 36177623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic Fatty Pancreas Disease: Clinical Consequences.
    Dite P; Blaho M; Bojkova M; Jabandziev P; Kunovsky L
    Dig Dis; 2020; 38(2):143-149. PubMed ID: 31865317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease.
    Pagkali A; Makris A; Brofidi K; Agouridis AP; Filippatos TD
    Diabetes Metab Syndr Obes; 2024; 17():283-294. PubMed ID: 38283640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty pancreas disease and pancreatic exocrine insufficiency: pilot study and systematic review.
    Maetzel H; Rutkowski W; Panic N; Mari A; Hedström A; Kulinski P; Stål P; Petersson S; Brismar TB; Löhr JM; Vujasinovic M
    Scand J Gastroenterol; 2023; 58(9):1030-1037. PubMed ID: 37088949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty pancreas disease: An emerging clinical challenge.
    Zhang CL; Wang JJ; Li JN; Yang Y
    World J Clin Cases; 2021 Aug; 9(23):6624-6638. PubMed ID: 34447810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Pancreas Disease.
    Shah N; Rocha JP; Bhutiani N; Endashaw O
    Nutr Clin Pract; 2019 Oct; 34 Suppl 1():S49-S56. PubMed ID: 31535735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression.
    Singh RG; Yoon HD; Wu LM; Lu J; Plank LD; Petrov MS
    Metabolism; 2017 Apr; 69():1-13. PubMed ID: 28285638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 diabetes: Does pancreatic fat really matter?
    Guglielmi V; Sbraccia P
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 28984071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study.
    Wu WC; Wang CY
    Cardiovasc Diabetol; 2013 May; 12():77. PubMed ID: 23688357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between pancreas steatosis and metabolic syndrome: A systematic review and meta-analysis.
    Bi Y; Wang JL; Li ML; Zhou J; Sun XL
    Diabetes Metab Res Rev; 2019 Jul; 35(5):e3142. PubMed ID: 30767421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of non-alcoholic fatty pancreas disease on glucose metabolism.
    Yu TY; Wang CY
    J Diabetes Investig; 2017 Nov; 8(6):735-747. PubMed ID: 28371475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transabdominal ultrasonography of the pancreas is superior to that of the liver for detection of ectopic fat deposits resulting from metabolic syndrome.
    Li S; Su L; Lv G; Zhao W; Chen J
    Medicine (Baltimore); 2017 Sep; 96(37):e8060. PubMed ID: 28906401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat.
    Della Corte C; Mosca A; Majo F; Lucidi V; Panera N; Giglioni E; Monti L; Stronati L; Alisi A; Nobili V
    Clin Endocrinol (Oxf); 2015 Nov; 83(5):656-62. PubMed ID: 26201937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of non-alcoholic fatty pancreatic disease among the Egyptian population and the value of serum fatty acid binding protein-1 (FABP-1) as a non-invasive biomarker.
    Okasha HH; Hegazy MA; Shaker O; Elfatah YA; El-Sawy SS; Abdelfatah D; Abdellatef A
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102364. PubMed ID: 38788255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease.
    Catanzaro R; Cuffari B; Italia A; Marotta F
    World J Gastroenterol; 2016 Sep; 22(34):7660-75. PubMed ID: 27678349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study.
    Lesmana CR; Pakasi LS; Inggriani S; Aidawati ML; Lesmana LA
    BMC Gastroenterol; 2015 Dec; 15():174. PubMed ID: 26652175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.